Globus Medical/$GMED
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Globus Medical
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
- Ticker
- $GMED
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 6,000
- Headquarters
- Audubon, United States
- Website
- www.globusmedical.com
Globus Medical Metrics
BasicAdvanced
$10B
19.50
$3.91
0.95
-
Price and volume
Market cap
$10B
Beta
0.95
52-week high
$101.40
52-week low
$56.66
Average daily volume
1.5M
Financial strength
Current ratio
4.622
Quick ratio
2.784
Long term debt to equity
0.02
Total debt to equity
0.023
Profitability
EBITDA (TTM)
1,010.295
Gross margin (TTM)
68.98%
Net profit margin (TTM)
17.03%
Operating margin (TTM)
23.22%
Effective tax rate (TTM)
18.89%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
8.74%
Return on equity (TTM)
11.81%
Valuation
Price to earnings (TTM)
19.5
Price to revenue (TTM)
3.269
Price to book
2.15
Price to tangible book (TTM)
3.88
Price to free cash flow (TTM)
13.782
Free cash flow yield (TTM)
7.26%
Free cash flow per share (TTM)
5.532
Growth
Revenue change (TTM)
19.74%
Earnings per share change (TTM)
51.94%
3-year revenue growth (CAGR)
42.06%
10-year revenue growth (CAGR)
18.96%
3-year earnings per share growth (CAGR)
25.03%
10-year earnings per share growth (CAGR)
12.26%
What the Analysts think about Globus Medical
Analyst ratings (Buy, Hold, Sell) for Globus Medical stock.
Analyst projections of the future price of Globus Medical stock.
Bulls say / Bears say
The core spine franchise is gaining share. Second-quarter US Spine revenue grew 7%, international spine grew 14% as reported, and total revenue excluding Nevro grew 9%. (Globus Medical, Globus Medical)
Operating leverage is becoming a major earnings driver. Adjusted gross margin increased by 200 basis points in the second quarter, adjusted EBITDA margin reached 35.4%, and the company raised full-year non-GAAP EPS guidance to $4.95–$5.05. (Globus Medical, Exa)
Globus is extending its robotics and imaging ecosystem internationally. The CE mark for Excelsius3D enables commercial sales in the European Union and United Kingdom and links intraoperative imaging with the ExcelsiusGPS robotic-navigation platform. (Globus Medical)
Nevro and Enabling Technologies remain the main weak spots. Management said second-quarter growth was 9% excluding Nevro, while it identified the Nevro recovery and the Enabling Technologies strategy change as downside risks to its guidance. (Exa, Globus Medical)
The revenue outlook was unchanged even though adjusted EPS guidance increased. That puts more of the earnings case on sustained margin improvement, operating leverage and acquisition synergies rather than faster sales growth. (Longbridge, Globus Medical)
Reported earnings weakened in the second quarter: GAAP net income fell 25.3% and diluted EPS fell 26.2%. The comparison was distorted by a prior-year Nevro bargain-purchase gain, but the gap between GAAP and adjusted results remains a risk for investors focused on reported profitability. (Globus Medical)
Data summarised monthly by Lightyear AI. Last updated on 25 Sept 2026.
Globus Medical Financial Performance
Revenues and expenses
Globus Medical Earnings Performance
Company profitability
Upcoming events
No upcoming events
Globus Medical News
AllArticlesVideos
Funds containing Globus Medical
AllUSDEURGBP
Fund name | Fund size | $GMED weighting |
|---|---|---|
L&G ROBO Global Robotics and Automation$ROBO | $1.7B | 1.21% |
L&G ROBO Global Robotics and Automation£ROBG | $1.7B | 1.21% |
iShares Ageing Population$AGED | $953M | 0.45% |
iShares Ageing Population€AGED | €822M | 0.45% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.24% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.